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the manufacturers of commercial products, suppliers of commercial 
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Sullivan and Dr. Jane Ballantyne. They would like to 
disclose that their employer, the University of Washington, received 
a contract payment from the Centers for Disease Control and 
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Planners have reviewed content to ensure there is no bias. 
This presentation will not include any discussion of the unlabeled
use of a product or products under investigational use.
Objectives
At the conclusion of this session, the participant will be 
able to:
 Describe the evidence for the association between opioid 
dosage and opioid therapy benefits and harms.
 Compare and contrast immediate release and extended-
release/long-acting opioid formulations.
 Identify methods for calculating morphine milligram equivalent 
dosage.
 List the steps for titrating opioids to specific dosage 
thresholds.
 Identify best practices for opioid tapering and discontinuation.
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Evidence does not support safety of ER/LA 
opioids relative to immediate-release opioids
• Did not find evidence that ER/LA opioids are more 
effective or safer than immediate-release opioids
• Higher overdose risk initiating treatment with ER/LA 
opioids than with immediate-release opioids
• Disproportionate numbers of overdose deaths 
associated with methadone
Use immediate-release opioids
when starting
• When starting opioid therapy for chronic pain, clinicians 
should prescribe immediate-release opioids instead of 
extended-release/long-acting (ER/LA) opioids.
(Recommendation category A: Evidence type: 4)
Additional cautions for
• Methadone
• Transdermal fentanyl
• Immediate-release opioids combined with ER/LA opioids
Higher dosages add risk without clear benefit
• Benefits of high-dose opioids for chronic pain not 
established
• RCT*: no difference in pain, function between 
– Liberal dose escalation (average 52 MME)
– Maintenance of current dosage (average 40 MME)
• Opioid use associated with dose-dependent increased 
risk of serious harms, including fatal and nonfatal 
overdose 
*Naliboff BD, Wu SM, Schieffer B, et al. A randomized trial of 2 prescription strategies for 
opioid treatment of chronic nonmalignant pain. J Pain. 2011;12(2):288-296.
Dosages at or above 50 
MME per day increase risks 
for overdose by at least 2 
times the risk at less than 
20 MME per day. 
Overdose risk increases with opioid dosage
Higher opioid dosages associated with opioid 
use disorder
Edlund, MJ et al.The role of opioid prescription in incident opioid abuse & dependence among 
individuals with chronic noncancer pain. Clin J Pain 2014; 30: 557-564.
Use caution at any dose and 
avoid increasing to high dosages
• When opioids are started, clinicians should prescribe the 
lowest effective dosage. 
• Clinicians should use caution when prescribing opioids at 
any dosage, should carefully reassess evidence of 
individual benefits and risks when increasing dosage to 
≥50 morphine milligram equivalents (MME)/day, and 
should avoid increasing dosage to ≥90 MME/day or 
carefully justify a decision to titrate dosage to >90 
MME/day.
(Recommendation category A: Evidence type: 3)
What about patients already taking high 
dosages?
• Offer the opportunity to reevaluate continuation of 
high-dosage opioids in light of recent evidence
• For patients who agree to taper opioids to lower 
dosages, collaborate on a tapering plan
Calculate MME
1. Determine the total daily amount of 
each opioid the patient takes
2. Convert each to MMEs—multiply the 
dose for each opioid by the conversion 
factor. (see table)
3. Add them together. 
• Chart lists opioids and 
conversion factors for 
calculating milligram 
equivalents (MME)
• CAUTION: Do not use to 
convert one opioid to 
another
Calculating morphine milligram equivalents 
(MME)
CAUTION: 
Do not use 
to convert 
one opioid 
to another
Offer a taper if opioids cause 
harm or are not helping
• Clinicians should evaluate benefits and harms with 
patients within 1 to 4 weeks of starting opioid therapy for 
chronic pain or of dose escalation. 
• Clinicians should evaluate benefits and harms of 
continued therapy with patients every 3 months or more 
frequently. 
• If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and 
work with patients to taper opioids to lower dosages or to 
taper and discontinue opioids.
(Recommendation category A: Evidence type: 4)
Taper slowly enough to minimize withdrawal 
• 10% per week is a reasonable starting point
• Some patients do better with slower tapers - 10%/month
• Consider more rapid taper when needed for safety
• Access appropriate expertise during pregnancy 
• Optimize pain management and support
⁻ Anticipate hyperalgesia immediately after tapering
⁻ Over the long term, most patients report improved 
function without worse pain
New Resource
Available under the Clinical Tools section of our Guideline resources:  
http://www.cdc.gov/drugoverdose/prescribing/resources.html
Connect With Us
Find more information on drug overdose 
and the Guideline:
• www.cdc.gov/drugoverdose
• www.cdc.gov/drugoverdose/prescribing/guideline
Are you on Twitter?
• Follow @DebHouryCDC and @CDCInjury for 
useful information and important Guideline 
updates.
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• www.cdc.gov/injury/socialmedia
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• Ms. Brown is 67 years old and has spinal stenosis
• She has had steadily worsening symptoms of leg pain, 
lower back pain, leg numbness and tingling, and 
difficulty walking
• She now finds it difficult to start moving and ambulating 
in the mornings
• She is motivated to get as well as she can without 
medication, and has been doing aqua aerobics and 
graded exercise under the supervision of therapists
• She has tried amitriptyline, gabapentin, and tramadol, 
but none of these helped
• Her clinician suggested a trial of low dose strong opioid
• She agreed
CASE:  MS. BROWN
WHICH OPIOID?
• Choose something simple with simple 
pharmacokinetics and pharmacodynamics
• This makes the treatment much safer and 
easier to manage by patients
• Do not use any of the long acting opioids when 
starting opioid therapy in an opioid naïve patient
• Long acting opioids include ER/LA opioids, 
methadone and transdermal fentanyl (fentanyl 
patches)
When starting opioids for chronic 
pain, prescribe IR not ER/LA opioids
• Choose predictable pharmacology to minimize overdose risk
• In general, avoid IR combined with ER/LA opioids
• Methadone should not be the first choice for an ER/LA opioid
– Only providers familiar with methadone’s unique risk and who are 
prepared to educate and closely monitor their patients should consider 
prescribing it for pain.
• Only consider prescribing transdermal fentanyl if familiar with 
the dosing and absorption properties and prepared to educate 
patients about its use.
From the supporting text for Recommendation #4 from the CDC Guideline for 
Prescribing Opioids for Chronic Pain. Recommendation category: A; Evidence type: 4
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WHY NOT START WITH LONG ACTING 
OPIOIDS?
• Dosage forms for ER/LA and transdermal fentanyl 
are too high for opioid naïve patients, especially 
elderly patients
• Most patients prefer taking opioids as needed and 
not round the clock
• Most patients find it easier to control their usage if 
they are taking opioid as needed and not round 
the clock
• Overall doses tend to be much lower if IR opioids 
are taken intermittently and no opioid is taken 
round the clock
IS THERE A ROLE FOR LONG-ACTING OPIOIDS?
• Yes, but not at the start of treatment
• Yes, when treating end-of-life pain and 
some long-term pain conditions
• Yes, when the patient has difficulty 
controlling usage (e.g. has a substance 
use disorder)
• Never in conjunction with IR opioids except 
during palliative or end-of-life pain care
WHY NOT METHADONE?
• Methadone has very complicated pharmacokinetics
• There are possible cardiac effects including QT 
prolongation
• There are many drug interactions
• Clearance is idiosyncratic, unpredictable and usually 
delayed
• Methadone is hard to get off
• Methadone should be reserved for specialists, cancer 
pain or addiction treatment
WHY NOT TRANSDERMAL FENTANYL?
• Even the lowest dose is too high for start of 
therapy
• Absorption can be unreliable
• Heat (e.g. hot showers or baths) can 
release medication suddenly leading to 
overdose
• Cannot provide intermittent or as needed 
doses
THE CHOICE FOR MS. BROWN
2.5 mg oxycodone (1/2 tablet) every 4 
hours as needed
When opioids are started, 
prescribe the lowest effective dose
• Use caution when prescribing opioids at any 
dosage
• Carefully reassess evidence of individual benefits 
and risks when increasing dosage to ≥50 
morphine milligram equivalents (MME)/day
• Avoid increasing dosage to ≥90 MME/day or 
carefully justify a decision to titrate dosage to >90 
MME/day.
(Recommendation category: A; Evidence type: 3)
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AT FOLLOW-UP:  MS. BROWN
• She returned to the clinic the following 
week and reported no improvement but 
tolerating opioid well and taking it 4 times 
daily
• Her dose was increased to try and get an 
effect
• After 2 further dose increases, she 
stabilized at 5 mg 4 hrly as needed, up to 
times daily
Re-evaluate benefits and harms 
of opioids, and continue therapy 
only as a deliberate decision
• Clinicians should evaluate benefits and harms with 
patients within 1 to 4 weeks of starting opioid therapy for 
chronic pain or of dose escalation. 
• Clinicians should evaluate benefits and harms of 
continued therapy with patients every 3 months or more 
frequently. 
• If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and 
work with patients to taper opioids to lower dosages or to 
taper and discontinue opioids.
(Recommendation category: A; Evidence type: 4)
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3 MONTH FOLLOW-UP: MS. BROWN
• At her 3 month follow up she came with 
her daughter who said her mother was 
drowsy all the time, and getting out and 
about even less that before
• The decision was made to taper her off 
the opioid
HOW TO DO A STRAIGHTFORWARD TAPER
• Do not try to taper too quickly, even for 
someone who hasn’t been on opioids for 
very long
• A reasonable regime would be:
10% reduction per week until off
• Warn about possible withdrawal symptoms 
and be prepared to treat withdrawal if it 
occurs
CASE:  MR. CASEY
• Mr. Casey is a 55 year-old self-employed truck 
driver who has had back pain for 7 years, starting 
with a back sprain injury
• He initially had a disc protrusion but that has 
resolved and he now has an MRI consistent with 
age and a normal exam
• He has been treated with opioids since the initial 
sprain injury
• His current regime is 30 mg oxycontin 3 times 
daily with 30 mg oxycodone 6 times daily as 
needed (MME 405)
CASE OF MR. CASEY CONTINUED:
• He has tried other medical and non medical 
treatments but says none of them work
• He works night to try and make up for time lost 
during painful episodes
• He doesn’t remember what it’s like to sleep well
• His wife of 18 years recently asked him to leave 
because he is dragging down the family
• He is convinced that opioids are the only thing 
that enable to work
WHAT ARE YOU GOING TO DO?
• His opioid dose is higher than currently 
recommended
• His function is poor and his life is in tatters
• He is almost certainly dependent on opioids
• It will be hard to persuade him to taper and hard 
to achieve a taper
• He will need a lot of ancillary help if he is going 
to improve
Re-evaluate benefits and harms 
of opioids, and continue therapy 
only as a deliberate decision
• Clinicians should evaluate benefits and harms with 
patients within 1 to 4 weeks of starting opioid therapy for 
chronic pain or of dose escalation. 
• Clinicians should evaluate benefits and harms of 
continued therapy with patients every 3 months or more 
frequently. 
• If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and 
work with patients to taper opioids to lower dosages or to 
taper and discontinue opioids.
(Recommendation category: A; Evidence type: 4)
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BASIC PRINCIPLES OF TAPERING IN A LONG-TERM 
OPIOID TREATED OR OPIOID DEPENDENT PATIENT
1. Spend time convincing the patient that tapering is the right 
thing to do (This may take more than one visit)
2. Taper slowly     e.g. 10% reduction per month
3. Be prepared to stop and give it a rest for a while if it gets 
difficult
4. As long as the trend is downwards, the amount of time it 
takes doesn’t matter
5. Never go up
BASIC PRINCIPLES CONTINUED:
6. If surgery or trauma intervene, always 
go back to the pre-event dose ASAP
7. If it is necessary or desirable to do a 
rapid taper, buprenorphine is a useful 
tool
8. Buprenorphine is a useful tool anyway  
GET BUPRENORPHINE TRAINING
• Work with patients to taper opioids down or off when 
o no sustained clinically meaningful improvement in pain and 
function 
o opioid dosages >50 MME/day without evidence of benefit
o concurrent benzodiazepines that can’t be tapered off
o patients request dosage reduction or discontinuation 
o patients experience overdose, other serious adverse events, 
warning signs. 
• Taper slowly enough to minimize opioid withdrawal 
o A decrease of 10% per week is a reasonable starting point
• Access appropriate expertise for tapering during 
pregnancy
• Optimize nonopioid pain management and psychosocial 
support
TAPERING OPIOIDS
START LOW AND GO SLOW
• Start with lowest effective dosage and increase by the 
smallest practical amount.
• If total opioid dosage >50 MME/day 
o reassess pain, function, and treatment 
o increase frequency of follow-up; and 
o consider offering naloxone.
• Avoid increasing opioid dosages to >90 MME/day.
• If escalating dosage requirements
o discuss other pain therapies with the patient 
o consider working with the patient to taper opioids down or off
o consider consulting a pain specialist.
IF PATIENT IS ALREADY RECEIVING A HIGH DOSAGE
 Offer established patients already taking >90 MME/day the 
opportunity to re-evaluate their continued use of high opioid 
dosages in light of recent evidence regarding the association 
of opioid dosage and overdose risk. 
 For patients who agree to taper opioids to lower dosages, 
collaborate with the patient on a tapering plan.
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
http://emergency.cdc.gov/coca/calls/2016/callinfo_081716.asp
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Continuing Education  for COCA Calls
All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
AAVSB/RACE) for COCA Calls are issued online through the CDC Training 
& Continuing Education Online system (http://www.cdc.gov/TCEOnline/).
Those who participated in today’s COCA Call and who wish to receive 
continuing education  should complete the online evaluation by 
September 16, 2016 with the course code WC2286. Those who will 
participate in the on demand activity and wish to receive continuing 
education should complete the online evaluation between September 17 , 
2016 and August 16, 2018 will use course code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
Join the COCA 
Mailing List
Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and 
response conferences and 
training opportunities
http://emergency.cdc.gov/coca 
Join Us on 
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for clinicians! “Like” 
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learn about upcoming 
COCA Calls, CDC 
guidance and 
recommendations, 
and other health alerts
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